nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB11—bile duct—gallbladder cancer	0.0556	0.201	CbGeAlD
Ponatinib—ABCB11—bile—gallbladder cancer	0.0427	0.155	CbGeAlD
Ponatinib—PDGFRA—gall bladder—gallbladder cancer	0.01	0.0362	CbGeAlD
Ponatinib—FGFR3—epithelium—gallbladder cancer	0.00912	0.033	CbGeAlD
Ponatinib—KIT—gall bladder—gallbladder cancer	0.00801	0.029	CbGeAlD
Ponatinib—FGFR4—liver—gallbladder cancer	0.00757	0.0274	CbGeAlD
Ponatinib—RET—epithelium—gallbladder cancer	0.00628	0.0227	CbGeAlD
Ponatinib—FGFR2—epithelium—gallbladder cancer	0.00597	0.0216	CbGeAlD
Ponatinib—FGFR4—lymph node—gallbladder cancer	0.00581	0.021	CbGeAlD
Ponatinib—TEK—epithelium—gallbladder cancer	0.00572	0.0207	CbGeAlD
Ponatinib—LYN—liver—gallbladder cancer	0.0052	0.0188	CbGeAlD
Ponatinib—FGFR3—liver—gallbladder cancer	0.00517	0.0187	CbGeAlD
Ponatinib—TEK—pancreas—gallbladder cancer	0.0051	0.0184	CbGeAlD
Ponatinib—SRC—epithelium—gallbladder cancer	0.00508	0.0184	CbGeAlD
Ponatinib—KDR—epithelium—gallbladder cancer	0.00468	0.0169	CbGeAlD
Ponatinib—SRC—pancreas—gallbladder cancer	0.00453	0.0164	CbGeAlD
Ponatinib—BCR—liver—gallbladder cancer	0.00447	0.0162	CbGeAlD
Ponatinib—FLT3—liver—gallbladder cancer	0.00444	0.0161	CbGeAlD
Ponatinib—KIT—epithelium—gallbladder cancer	0.00414	0.015	CbGeAlD
Ponatinib—FGFR1—liver—gallbladder cancer	0.00398	0.0144	CbGeAlD
Ponatinib—KIT—pancreas—gallbladder cancer	0.00369	0.0134	CbGeAlD
Ponatinib—LCK—liver—gallbladder cancer	0.00356	0.0129	CbGeAlD
Ponatinib—ABCB11—liver—gallbladder cancer	0.00348	0.0126	CbGeAlD
Ponatinib—BCR—lymph node—gallbladder cancer	0.00343	0.0124	CbGeAlD
Ponatinib—FLT3—lymph node—gallbladder cancer	0.0034	0.0123	CbGeAlD
Ponatinib—FGFR2—liver—gallbladder cancer	0.00338	0.0122	CbGeAlD
Ponatinib—TEK—liver—gallbladder cancer	0.00324	0.0117	CbGeAlD
Ponatinib—ABL1—pancreas—gallbladder cancer	0.00321	0.0116	CbGeAlD
Ponatinib—FGFR1—lymph node—gallbladder cancer	0.00305	0.011	CbGeAlD
Ponatinib—PDGFRA—liver—gallbladder cancer	0.00294	0.0106	CbGeAlD
Ponatinib—SRC—liver—gallbladder cancer	0.00288	0.0104	CbGeAlD
Ponatinib—RET—lymph node—gallbladder cancer	0.00273	0.00987	CbGeAlD
Ponatinib—LCK—lymph node—gallbladder cancer	0.00273	0.00987	CbGeAlD
Ponatinib—KDR—liver—gallbladder cancer	0.00265	0.00959	CbGeAlD
Ponatinib—TEK—lymph node—gallbladder cancer	0.00249	0.00899	CbGeAlD
Ponatinib—KIT—liver—gallbladder cancer	0.00235	0.0085	CbGeAlD
Ponatinib—PDGFRA—lymph node—gallbladder cancer	0.00225	0.00815	CbGeAlD
Ponatinib—SRC—lymph node—gallbladder cancer	0.00221	0.00799	CbGeAlD
Ponatinib—ABL1—liver—gallbladder cancer	0.00205	0.0074	CbGeAlD
Ponatinib—KDR—lymph node—gallbladder cancer	0.00203	0.00735	CbGeAlD
Ponatinib—CYP3A5—pancreas—gallbladder cancer	0.00188	0.0068	CbGeAlD
Ponatinib—KIT—lymph node—gallbladder cancer	0.0018	0.00651	CbGeAlD
Ponatinib—ABL1—lymph node—gallbladder cancer	0.00157	0.00567	CbGeAlD
Ponatinib—CYP2C8—liver—gallbladder cancer	0.00133	0.0048	CbGeAlD
Ponatinib—ABCG2—liver—gallbladder cancer	0.00129	0.00466	CbGeAlD
Ponatinib—CYP3A5—liver—gallbladder cancer	0.0012	0.00433	CbGeAlD
Ponatinib—ABCB1—epithelium—gallbladder cancer	0.00112	0.00406	CbGeAlD
Ponatinib—ABCB1—pancreas—gallbladder cancer	0.001	0.00361	CbGeAlD
Ponatinib—ABCG2—lymph node—gallbladder cancer	0.000989	0.00358	CbGeAlD
Ponatinib—CYP3A4—liver—gallbladder cancer	0.000898	0.00325	CbGeAlD
Ponatinib—CYP2D6—liver—gallbladder cancer	0.000884	0.0032	CbGeAlD
Ponatinib—ABCB1—liver—gallbladder cancer	0.000636	0.0023	CbGeAlD
Ponatinib—ABCB1—lymph node—gallbladder cancer	0.000488	0.00176	CbGeAlD
Ponatinib—KIT—Adaptive Immune System—EGFR—gallbladder cancer	7.71e-05	0.000107	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB4—gallbladder cancer	7.64e-05	0.000106	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—EGFR—gallbladder cancer	7.62e-05	0.000105	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB4—gallbladder cancer	7.62e-05	0.000105	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—ERBB2—gallbladder cancer	7.61e-05	0.000105	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—EGFR—gallbladder cancer	7.6e-05	0.000105	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—NRAS—gallbladder cancer	7.6e-05	0.000105	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—EGFR—gallbladder cancer	7.59e-05	0.000105	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—KRAS—gallbladder cancer	7.59e-05	0.000105	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—EGFR—gallbladder cancer	7.56e-05	0.000104	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB4—gallbladder cancer	7.54e-05	0.000104	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—HRAS—gallbladder cancer	7.52e-05	0.000104	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—KRAS—gallbladder cancer	7.42e-05	0.000103	CbGpPWpGaD
Ponatinib—LCK—Immune System—ERBB3—gallbladder cancer	7.37e-05	0.000102	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—NRAS—gallbladder cancer	7.36e-05	0.000102	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—NRAS—gallbladder cancer	7.33e-05	0.000101	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—EGFR—gallbladder cancer	7.32e-05	0.000101	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—EGFR—gallbladder cancer	7.3e-05	0.000101	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—KRAS—gallbladder cancer	7.29e-05	0.000101	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—KRAS—gallbladder cancer	7.29e-05	0.000101	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—BCL2—gallbladder cancer	7.23e-05	9.99e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TP53—gallbladder cancer	7.21e-05	9.97e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—KRAS—gallbladder cancer	7.2e-05	9.95e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—KRAS—gallbladder cancer	7.18e-05	9.93e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—KRAS—gallbladder cancer	7.17e-05	9.91e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—KRAS—gallbladder cancer	7.14e-05	9.87e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ERBB3—gallbladder cancer	7.09e-05	9.79e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—BCL2—gallbladder cancer	7.07e-05	9.78e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—NRAS—gallbladder cancer	7.07e-05	9.77e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—KRAS—gallbladder cancer	7.04e-05	9.73e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—ERBB2—gallbladder cancer	7.02e-05	9.7e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—NRAS—gallbladder cancer	7.02e-05	9.7e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—KRAS—gallbladder cancer	7e-05	9.68e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	6.97e-05	9.64e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB4—gallbladder cancer	6.96e-05	9.63e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ERBB3—gallbladder cancer	6.96e-05	9.62e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—BCL2—gallbladder cancer	6.95e-05	9.6e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—HRAS—gallbladder cancer	6.94e-05	9.59e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—HRAS—gallbladder cancer	6.93e-05	9.58e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—EGFR—gallbladder cancer	6.93e-05	9.57e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—KRAS—gallbladder cancer	6.91e-05	9.56e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—HRAS—gallbladder cancer	6.9e-05	9.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—KRAS—gallbladder cancer	6.9e-05	9.53e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—ERBB2—gallbladder cancer	6.87e-05	9.5e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—HRAS—gallbladder cancer	6.85e-05	9.47e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—ERBB3—gallbladder cancer	6.8e-05	9.4e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—ERBB2—gallbladder cancer	6.75e-05	9.33e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—ERBB2—gallbladder cancer	6.74e-05	9.32e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB4—gallbladder cancer	6.72e-05	9.29e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—EGFR—gallbladder cancer	6.71e-05	9.27e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—NRAS—gallbladder cancer	6.7e-05	9.26e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—EGFR—gallbladder cancer	6.67e-05	9.23e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—NRAS—gallbladder cancer	6.64e-05	9.18e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB3—gallbladder cancer	6.6e-05	9.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—BCL2—gallbladder cancer	6.59e-05	9.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB3—gallbladder cancer	6.59e-05	9.1e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	6.59e-05	9.1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—BCL2—gallbladder cancer	6.58e-05	9.09e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—HRAS—gallbladder cancer	6.57e-05	9.08e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—KRAS—gallbladder cancer	6.54e-05	9.04e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB3—gallbladder cancer	6.52e-05	9.01e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—ERBB2—gallbladder cancer	6.46e-05	8.93e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—HRAS—gallbladder cancer	6.45e-05	8.91e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—EGFR—gallbladder cancer	6.44e-05	8.9e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—ERBB2—gallbladder cancer	6.4e-05	8.85e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—EGFR—gallbladder cancer	6.39e-05	8.84e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—ERBB2—gallbladder cancer	6.39e-05	8.83e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—ERBB2—gallbladder cancer	6.34e-05	8.77e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—KRAS—gallbladder cancer	6.33e-05	8.76e-05	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—HRAS—gallbladder cancer	6.31e-05	8.72e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—KRAS—gallbladder cancer	6.31e-05	8.72e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—gallbladder cancer	6.25e-05	8.64e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—ERBB2—gallbladder cancer	6.23e-05	8.61e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—gallbladder cancer	6.22e-05	8.6e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—HRAS—gallbladder cancer	6.2e-05	8.57e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—HRAS—gallbladder cancer	6.19e-05	8.56e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—HRAS—gallbladder cancer	6.12e-05	8.46e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—HRAS—gallbladder cancer	6.1e-05	8.44e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—HRAS—gallbladder cancer	6.1e-05	8.43e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—KRAS—gallbladder cancer	6.08e-05	8.41e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—HRAS—gallbladder cancer	6.07e-05	8.39e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—EGFR—gallbladder cancer	6.05e-05	8.37e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—NRAS—gallbladder cancer	6.05e-05	8.36e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—KRAS—gallbladder cancer	6.04e-05	8.35e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—NRAS—gallbladder cancer	6.03e-05	8.34e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB3—gallbladder cancer	6.02e-05	8.32e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—HRAS—gallbladder cancer	5.98e-05	8.27e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—HRAS—gallbladder cancer	5.95e-05	8.23e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—NRAS—gallbladder cancer	5.93e-05	8.2e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—ERBB2—gallbladder cancer	5.91e-05	8.17e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—ERBB2—gallbladder cancer	5.9e-05	8.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—HRAS—gallbladder cancer	5.88e-05	8.12e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—HRAS—gallbladder cancer	5.86e-05	8.1e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	5.85e-05	8.09e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB3—gallbladder cancer	5.81e-05	8.03e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—BCL2—gallbladder cancer	5.8e-05	8.02e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—NRAS—gallbladder cancer	5.79e-05	8.01e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—BCL2—gallbladder cancer	5.77e-05	7.98e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—KRAS—gallbladder cancer	5.77e-05	7.97e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KRAS—gallbladder cancer	5.72e-05	7.9e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—ERBB2—gallbladder cancer	5.63e-05	7.79e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—ERBB2—gallbladder cancer	5.63e-05	7.78e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—ERBB2—gallbladder cancer	5.61e-05	7.75e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HRAS—gallbladder cancer	5.56e-05	7.69e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—EGFR—gallbladder cancer	5.51e-05	7.62e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB4—gallbladder cancer	5.51e-05	7.61e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—EGFR—gallbladder cancer	5.5e-05	7.6e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—HRAS—gallbladder cancer	5.38e-05	7.44e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—HRAS—gallbladder cancer	5.36e-05	7.41e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—NRAS—gallbladder cancer	5.34e-05	7.38e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—EGFR—gallbladder cancer	5.28e-05	7.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—NRAS—gallbladder cancer	5.23e-05	7.23e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—KRAS—gallbladder cancer	5.2e-05	7.19e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—KRAS—gallbladder cancer	5.19e-05	7.18e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HRAS—gallbladder cancer	5.17e-05	7.15e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—NRAS—gallbladder cancer	5.13e-05	7.1e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—HRAS—gallbladder cancer	5.13e-05	7.1e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—NRAS—gallbladder cancer	5.13e-05	7.09e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—gallbladder cancer	5.13e-05	7.09e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—KRAS—gallbladder cancer	5.11e-05	7.06e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—gallbladder cancer	5.08e-05	7.02e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KRAS—gallbladder cancer	4.99e-05	6.89e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NRAS—gallbladder cancer	4.91e-05	6.79e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—HRAS—gallbladder cancer	4.9e-05	6.78e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB4—gallbladder cancer	4.88e-05	6.74e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—NRAS—gallbladder cancer	4.87e-05	6.73e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—EGFR—gallbladder cancer	4.87e-05	6.73e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—HRAS—gallbladder cancer	4.86e-05	6.72e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—NRAS—gallbladder cancer	4.86e-05	6.72e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NRAS—gallbladder cancer	4.83e-05	6.67e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—EGFR—gallbladder cancer	4.76e-05	6.58e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB3—gallbladder cancer	4.76e-05	6.58e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—BCL2—gallbladder cancer	4.75e-05	6.57e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—NRAS—gallbladder cancer	4.74e-05	6.55e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—EGFR—gallbladder cancer	4.68e-05	6.47e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—EGFR—gallbladder cancer	4.67e-05	6.46e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—ERBB2—gallbladder cancer	4.62e-05	6.38e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KRAS—gallbladder cancer	4.6e-05	6.35e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—gallbladder cancer	4.54e-05	6.27e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KRAS—gallbladder cancer	4.5e-05	6.22e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NRAS—gallbladder cancer	4.5e-05	6.22e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NRAS—gallbladder cancer	4.49e-05	6.2e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EGFR—gallbladder cancer	4.48e-05	6.19e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ERBB2—gallbladder cancer	4.44e-05	6.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—EGFR—gallbladder cancer	4.44e-05	6.14e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—EGFR—gallbladder cancer	4.43e-05	6.12e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—HRAS—gallbladder cancer	4.42e-05	6.12e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—KRAS—gallbladder cancer	4.42e-05	6.11e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KRAS—gallbladder cancer	4.41e-05	6.1e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—HRAS—gallbladder cancer	4.41e-05	6.1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—EGFR—gallbladder cancer	4.4e-05	6.08e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ERBB2—gallbladder cancer	4.36e-05	6.03e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—gallbladder cancer	4.34e-05	6e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—EGFR—gallbladder cancer	4.32e-05	5.97e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—NRAS—gallbladder cancer	4.29e-05	5.93e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NRAS—gallbladder cancer	4.28e-05	5.92e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NRAS—gallbladder cancer	4.27e-05	5.9e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—ERBB2—gallbladder cancer	4.26e-05	5.89e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—gallbladder cancer	4.24e-05	5.86e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KRAS—gallbladder cancer	4.23e-05	5.85e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB3—gallbladder cancer	4.22e-05	5.83e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—BCL2—gallbladder cancer	4.21e-05	5.82e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KRAS—gallbladder cancer	4.19e-05	5.8e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KRAS—gallbladder cancer	4.18e-05	5.78e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KRAS—gallbladder cancer	4.15e-05	5.74e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB2—gallbladder cancer	4.14e-05	5.72e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB2—gallbladder cancer	4.13e-05	5.71e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EGFR—gallbladder cancer	4.1e-05	5.67e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB2—gallbladder cancer	4.09e-05	5.65e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EGFR—gallbladder cancer	4.09e-05	5.65e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—KRAS—gallbladder cancer	4.08e-05	5.64e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—gallbladder cancer	3.91e-05	5.4e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—gallbladder cancer	3.91e-05	5.4e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—gallbladder cancer	3.9e-05	5.39e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—gallbladder cancer	3.89e-05	5.37e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—gallbladder cancer	3.87e-05	5.35e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—gallbladder cancer	3.86e-05	5.34e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—gallbladder cancer	3.82e-05	5.29e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB2—gallbladder cancer	3.78e-05	5.22e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—gallbladder cancer	3.76e-05	5.2e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—gallbladder cancer	3.76e-05	5.19e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—gallbladder cancer	3.75e-05	5.19e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—gallbladder cancer	3.69e-05	5.1e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—gallbladder cancer	3.68e-05	5.09e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—gallbladder cancer	3.67e-05	5.08e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB2—gallbladder cancer	3.64e-05	5.04e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—gallbladder cancer	3.6e-05	4.97e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—gallbladder cancer	3.56e-05	4.93e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—gallbladder cancer	3.56e-05	4.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—gallbladder cancer	3.53e-05	4.88e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—gallbladder cancer	3.51e-05	4.86e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—gallbladder cancer	3.47e-05	4.79e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—gallbladder cancer	3.38e-05	4.67e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—gallbladder cancer	3.32e-05	4.59e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—gallbladder cancer	3.29e-05	4.55e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—gallbladder cancer	3.28e-05	4.54e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—gallbladder cancer	3.27e-05	4.53e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—gallbladder cancer	3.24e-05	4.48e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—gallbladder cancer	3.2e-05	4.42e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—gallbladder cancer	3.15e-05	4.35e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—gallbladder cancer	3.14e-05	4.34e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—gallbladder cancer	3.14e-05	4.33e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—gallbladder cancer	3.13e-05	4.33e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—gallbladder cancer	3.12e-05	4.31e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—gallbladder cancer	3.11e-05	4.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—gallbladder cancer	3.08e-05	4.26e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—gallbladder cancer	3.02e-05	4.18e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—gallbladder cancer	3.02e-05	4.18e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—gallbladder cancer	2.99e-05	4.13e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—gallbladder cancer	2.96e-05	4.09e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—gallbladder cancer	2.91e-05	4.02e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—gallbladder cancer	2.87e-05	3.97e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—gallbladder cancer	2.87e-05	3.97e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—gallbladder cancer	2.86e-05	3.96e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—gallbladder cancer	2.86e-05	3.95e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—gallbladder cancer	2.83e-05	3.92e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—gallbladder cancer	2.79e-05	3.86e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—gallbladder cancer	2.77e-05	3.83e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—gallbladder cancer	2.71e-05	3.75e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—gallbladder cancer	2.7e-05	3.74e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—gallbladder cancer	2.68e-05	3.7e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—gallbladder cancer	2.64e-05	3.65e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—gallbladder cancer	2.62e-05	3.62e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—gallbladder cancer	2.59e-05	3.57e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—gallbladder cancer	2.57e-05	3.55e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—gallbladder cancer	2.54e-05	3.51e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—gallbladder cancer	2.53e-05	3.49e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—gallbladder cancer	2.47e-05	3.42e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—gallbladder cancer	2.47e-05	3.42e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—gallbladder cancer	2.43e-05	3.36e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—gallbladder cancer	2.41e-05	3.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—gallbladder cancer	2.4e-05	3.32e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—gallbladder cancer	2.39e-05	3.3e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—gallbladder cancer	2.37e-05	3.28e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—gallbladder cancer	2.3e-05	3.19e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—gallbladder cancer	2.3e-05	3.18e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—gallbladder cancer	2.28e-05	3.15e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—gallbladder cancer	2.27e-05	3.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—gallbladder cancer	2.12e-05	2.93e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—gallbladder cancer	2.1e-05	2.9e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—gallbladder cancer	2.07e-05	2.86e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—gallbladder cancer	2.03e-05	2.8e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—gallbladder cancer	2.01e-05	2.78e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—gallbladder cancer	1.96e-05	2.7e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—gallbladder cancer	1.83e-05	2.53e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—gallbladder cancer	1.74e-05	2.4e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—gallbladder cancer	1.73e-05	2.39e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—gallbladder cancer	1.66e-05	2.3e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—gallbladder cancer	1.54e-05	2.13e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—gallbladder cancer	1.47e-05	2.03e-05	CbGpPWpGaD
